Skip to main content
Erschienen in: International Journal of Hematology 6/2017

07.03.2017 | Original Article

Pediatric follicular lymphoma in Japan

verfasst von: Ryoji Kobayashi, Fumiko Tanaka, Atsuko Nakazawa, Jun-ichi Ueyama, Shosuke Sunami, Tetsuo Mitsui, Yuhki Koga, Takeshi Mori, Tomoo Osumi, Reiji Fukano, Kentaro Ohki, Masahiro Sekimizu, Naoto Fujita, Michi Kamei, Tetsuya Mori, Lymphoma Committee and Japanese Pediatric Leukemia/Lymphoma Study Group

Erschienen in: International Journal of Hematology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Follicular lymphoma (FL) is quite rare in children. There have been only two major reports on pediatric FL. The present retrospective study on pediatric FL in Japan, including FL with diffuse large B cell lymphoma (DLBCL), analyzed data from 1991 to 2014. Twenty-two patients with pediatric FL were analyzed. Sixteen patients were boys and six were girls. Median age of onset was 9 years (range 4–17 years). In 11 patients, DLBCL co-existed with FL. The initial lesions involved cervical lesions in 16 patients, and the abdomen in six. With regard to stage of disease at diagnosis, 17 patients were at stage I or II, four were at stage III, and one was at stage IV. Chemotherapy was administered in 18 patients, and only resection was performed in four patients. Mature B lymphoma regimens were selected for 17 patients who received chemotherapy. Although two patients relapsed, all patients are currently alive and disease free. The median follow-up period was 54.5 months (range 6–126 months). Patients having FL with DLBCL were younger compared with those having FL, and this disease was more frequently observed in female patients. Our data revealed that FL in Japanese children is a tumor with good prognosis, as in reports from the United States and Europe.
Literatur
1.
Zurück zum Zitat Kobayashi R, Sunami S, Mitsui T, Nakazawa A, Koga Y, Mori T, et al. Treatment of pediatric lymphoma in Japan: current status and plans for the future. Pediatr Int. 2015;57:523–34.CrossRefPubMed Kobayashi R, Sunami S, Mitsui T, Nakazawa A, Koga Y, Mori T, et al. Treatment of pediatric lymphoma in Japan: current status and plans for the future. Pediatr Int. 2015;57:523–34.CrossRefPubMed
2.
Zurück zum Zitat Lorsbach RB, Shay-Seymore D, Moore J, Banks PM, Hasserjian RP, Sandlund JT, et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood. 2002;99:1959–64.CrossRefPubMed Lorsbach RB, Shay-Seymore D, Moore J, Banks PM, Hasserjian RP, Sandlund JT, et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood. 2002;99:1959–64.CrossRefPubMed
3.
Zurück zum Zitat Oschlies I, Salaverria I, Mahn F, Meinhardt A, Zimmermann M, Woessmann W, et al. Pediatric follicular lymphoma—a clinico-pathological study of a population-based series of patients treated within the non-Hodgkin’s Lymphoma–Berlin-Frankfurt-Munster (NHL–BFM) multicenter trials. Haematologica. 2010;95:253–9.CrossRefPubMed Oschlies I, Salaverria I, Mahn F, Meinhardt A, Zimmermann M, Woessmann W, et al. Pediatric follicular lymphoma—a clinico-pathological study of a population-based series of patients treated within the non-Hodgkin’s Lymphoma–Berlin-Frankfurt-Munster (NHL–BFM) multicenter trials. Haematologica. 2010;95:253–9.CrossRefPubMed
4.
Zurück zum Zitat Harris NL, Nathwani BN, Swerdlow SH, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. Harris NL, Nathwani BN, Swerdlow SH, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
5.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed
6.
Zurück zum Zitat Disease registration committee, Japanese Society of Pediatric Hematology and Oncology. The report of epidemiologic study from 2009 to 2011. Jpn J Pediatr Hematol/Oncol. 2013;50:462–78. Disease registration committee, Japanese Society of Pediatric Hematology and Oncology. The report of epidemiologic study from 2009 to 2011. Jpn J Pediatr Hematol/Oncol. 2013;50:462–78.
7.
Zurück zum Zitat Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–62.CrossRefPubMed Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–62.CrossRefPubMed
8.
Zurück zum Zitat Swerdlow S, Campo E, Harris N. World Health Organization classification of tumours of aematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. Swerdlow S, Campo E, Harris N. World Health Organization classification of tumours of aematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
9.
Zurück zum Zitat Attarbaschi A, Beishuizen A, Mann G, Rosolen A, Mori T, Uyttebroeck A, et al. European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the international Berlin-Frankfurt-Münster (i-BFM) Study Group. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a “Watch and wait” strategy after complete resection. Ann Hematol. 2013;92:1537–41.CrossRefPubMed Attarbaschi A, Beishuizen A, Mann G, Rosolen A, Mori T, Uyttebroeck A, et al. European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the international Berlin-Frankfurt-Münster (i-BFM) Study Group. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a “Watch and wait” strategy after complete resection. Ann Hematol. 2013;92:1537–41.CrossRefPubMed
10.
Zurück zum Zitat Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol. 1995;13:1726–33.CrossRefPubMed Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol. 1995;13:1726–33.CrossRefPubMed
11.
Zurück zum Zitat Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454–9.CrossRefPubMed Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454–9.CrossRefPubMed
12.
Zurück zum Zitat Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:5165–9.CrossRefPubMed Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:5165–9.CrossRefPubMed
13.
Zurück zum Zitat Bains P, Al Tourah A, Campbell BA, Pickles T, Gascoyne RD, Connors JM, et al. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol. 2013;24:428–32.CrossRefPubMed Bains P, Al Tourah A, Campbell BA, Pickles T, Gascoyne RD, Connors JM, et al. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol. 2013;24:428–32.CrossRefPubMed
14.
Zurück zum Zitat Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15:1587–94.CrossRefPubMed Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15:1587–94.CrossRefPubMed
Metadaten
Titel
Pediatric follicular lymphoma in Japan
verfasst von
Ryoji Kobayashi
Fumiko Tanaka
Atsuko Nakazawa
Jun-ichi Ueyama
Shosuke Sunami
Tetsuo Mitsui
Yuhki Koga
Takeshi Mori
Tomoo Osumi
Reiji Fukano
Kentaro Ohki
Masahiro Sekimizu
Naoto Fujita
Michi Kamei
Tetsuya Mori
Lymphoma Committee and Japanese Pediatric Leukemia/Lymphoma Study Group
Publikationsdatum
07.03.2017
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 6/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2209-1

Weitere Artikel der Ausgabe 6/2017

International Journal of Hematology 6/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.